中慧生物港股上市：大涨160% 公司市值132亿港元

Group 1 - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (referred to as "Zhonghui Biotech") successfully listed on the Hong Kong Stock Exchange, attracting significant market attention due to its stock price performance [1] - Zhonghui Biotech issued 33.4426 million shares at a price of HKD 12.9 per share, raising a total of HKD 431 million, with the opening price soaring to HKD 33, representing a substantial increase of 156% from the issue price [1] - Following the stock price surge, the company's market capitalization reached approximately HKD 13.2 billion [1] Group 2 - Zhonghui Biotech focuses on vaccine research, manufacturing, and commercialization, currently possessing two core products: a quadrivalent influenza virus subunit vaccine and an in-development lyophilized human rabies vaccine [3] - The quadrivalent influenza virus subunit vaccine has been approved for market release by the National Medical Products Administration, indicating a broad market potential [3] - Despite its promising product pipeline, Zhonghui Biotech has reported financial losses in recent years, with losses of CNY 425 million and CNY 259 million expected in 2023 and 2024, respectively, and a loss of CNY 87.32 million in the first three months of 2025 [3]